← Back to Search

Corticosteroid

Acthar for Rheumatoid Arthritis

Phase 4
Recruiting
Led By Veena K Ranganath, M.D., M.S.
Research Sponsored by Veena Ranganath, MD, MS
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 4 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing whether Acthar, a medication used to treat flares in RA, can help improve symptoms as measured by MSUS and disease activity scores.

Who is the study for?
This trial is for adults over 18 with Rheumatoid Arthritis who have a certain level of disease activity and inflammation. They should be on stable RA medications but not have used Acthar recently or received live vaccines in the past 6 weeks.
What is being tested?
The study tests if Acthar can improve inflammation and disease activity in RA flares, measured by ultrasound scores and other assessments. It's to see how effective Acthar is during these flare-ups.
What are the potential side effects?
Acthar may cause side effects such as increased blood pressure, mood changes, weight gain, high blood sugar levels, increased risk of infections, digestive issues, and possible allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
DAS28
Ultrasound Power Doppler Score
Secondary study objectives
HAQ-DI
Ultrasonography

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Group I: 40 UnitsActive Control1 Intervention
40 units of Acthar per week
Group II: 80 UnitsActive Control1 Intervention
80 units of Acthar twice per week

Find a Location

Who is running the clinical trial?

Veena Ranganath, MD, MSLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Rheumatoid Arthritis
40 Patients Enrolled for Rheumatoid Arthritis
Dr. Veena RanganathLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Rheumatoid Arthritis
40 Patients Enrolled for Rheumatoid Arthritis
Veena K Ranganath, M.D., M.S.Principal InvestigatorUniversity of California, Los Angeles
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Rheumatoid Arthritis
40 Patients Enrolled for Rheumatoid Arthritis

Media Library

Acthar (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT02541955 — Phase 4
Rheumatoid Arthritis Research Study Groups: 40 Units, 80 Units
Rheumatoid Arthritis Clinical Trial 2023: Acthar Highlights & Side Effects. Trial Name: NCT02541955 — Phase 4
Acthar (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02541955 — Phase 4
Rheumatoid Arthritis Patient Testimony for trial: Trial Name: NCT02541955 — Phase 4
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top